Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. SUMM.L Share Price
  4. SUMM.L Share Regulatory News
  5. Price Monitoring Extension

Pin to quick picksSUMM.L Regulatory News (SUMM)

SUMM.L Information
  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Price Monitoring Extension

1 Oct 2019 14:00

RNS Number : 3752O
Summit Therapeutics PLC
01 October 2019
 

Price Monitoring Extension

The auction call period has been extended in this security by 5 minutes.

Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the execution occurs. A price monitoring extension is activated when the matching process would have otherwise resulted in an execution price that is a pre-determined percentage above or below the price of the most recent automated execution today.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PMEXFLFBKBFBFBB
1234
Date   Source Headline
3rd Apr 201912:00 pmGNWSummit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
2nd Apr 201912:00 pmGNWSummit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29th Mar 20195:45 pmGNWAward of Share Options
29th Mar 201911:15 amGNWFiling of Annual Report on Form 20-F
27th Mar 201911:00 amGNWFinal Results
25th Mar 201911:00 amGNWNotice of Results
18th Mar 201911:00 amGNWSummit Therapeutics to Present at Upcoming Conferences
14th Mar 201911:00 amGNWSummit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25th Feb 201912:00 pmGNWSummit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13th Feb 201912:00 pmGNWSummit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
8th Feb 201912:00 pmGNWSummit Therapeutics to Present at the BIO CEO & Investor Conference
15th Jan 20195:45 pmGNWHolding(s) in Company
14th Jan 201912:00 pmGNWAward of Restricted Stock Units
10th Jan 20194:15 pmGNWHolding(s) in Company
10th Jan 201911:30 amGNWHolding(s) in Company
10th Jan 20197:00 amGNWCompletion of $25 million Subscription
9th Jan 20194:45 pmGNWHolding(s) in Company
8th Jan 20197:00 amGNWUpdate on Admission
4th Jan 201912:30 pmGNWResult of General Meeting
2nd Jan 20199:40 amGNWHolding(s) in Company
18th Dec 201812:15 pmGNWHolding(s) in Company
17th Dec 20187:05 amGNWProposed Subscription to Raise $25m and Notice of General Meeting
17th Dec 20187:00 amGNWSummit Therapeutics Announces Departure of Chief Financial Officer
11th Dec 201812:00 pmGNW3rd Quarter Results
6th Dec 201812:00 pmGNWSummit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
30th Nov 20181:30 pmGNWHolding(s) in Company
12th Nov 201812:00 pmGNWSummit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
12th Nov 20187:00 amGNWAppointment of Joint Broker
7th Nov 201812:00 pmGNWSummit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
1st Nov 20184:34 pmGNWHolding(s) in Company
1st Nov 201811:00 amGNWSummit Recognises C. difficile Awareness Month
24th Oct 20184:15 pmGNWDirector/PDMR Shareholding
22nd Oct 20187:00 amGNWAward of Share Options
20th Sep 201812:00 pmGNWSummit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress
27th Dec 20177:00 amRNSAcquisition of Discuva Ltd
10th May 20122:04 pmRNSGrant of Options
30th Dec 200911:07 amRNSResult of GM
30th Dec 20097:00 amRNSResult of Placing and Open Offer
11th Dec 200912:53 pmRNSPlacing and Open Offer and Appointment of NOMAD
11th Dec 200912:40 pmRNSWellcome Trust Grant
31st Jan 20087:00 amRNSTrading Statement
16th Jan 20087:01 amRNSStart of Ph II clinical trial
6th Dec 20077:00 amRNSChange of Adviser
5th Nov 200711:18 amRNSDirector/PDMR Shareholding
30th Oct 20077:02 amRNSRe Agreement
30th Oct 20077:01 amRNSInterim Results
25th Oct 20074:07 pmRNSHolding in Company
23rd Oct 20077:02 amRNSClinical Update
12th Oct 20079:00 amRNSNotice of Results
2nd Oct 20077:01 amRNSResearch Donation
1234

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.